According to Coherent Market Insights, the global cell and gene therapy market size is estimated to be valued at USD 22.7 billion in 2023 and is expected to surpass USD 132.6 billion by 2030, growing at a CAGR of 28.7% from 2023 to 2030.
The global cell and gene therapy market is witnessing significant growth due to rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and genetic disorders. According to WHO, cancer is the second leading cause of death globally and was responsible for nearly 10 million deaths in 2020.
Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/2475
Growing
awareness regarding gene and cell therapy as a potential treatment for various
chronic diseases is further propelling market growth. Additionally, increasing
funding for cell and gene therapy projects and clinical trials by both public
and private organizations is augmenting the market expansion.
Market Trends Autologous cell
and gene therapies which use patient's own cells for treatment have gained
immense popularity in recent years. For instance, autologous CAR T-cell
therapies such as Yescarta and Kymriah have witnessed significant adoption
rates post FDA approval for treatment of blood cancer. This trend is expected
to continue during the forecast period with anticipated launch of several
autologous therapies targeting various cancer and genetic disorders.
Gene therapy
holds promising potential for treating many neurological disorders with underlying
genetic causes such as Parkinson's disease, Huntington's disease, Alzheimer's
disease, retinal disorders, and spinal muscular atrophy. Several gene therapy
candidates targeting neurological conditions are currently under clinical
trials. The U.S. FDA approved Zolgensma in May, 2019. It is the first gene
therapy approved to treat spinal muscular atrophy (SMA). This has further
accelerated research focus on developing gene therapies for other genetic
diseases. Cell and Gene
Therapy Market Report Coverage
Report
Coverage Details Market
Revenue in 2023 $22.7
billion Estimated
Value by 2030 $132.6
billion Growth
Rate Poised
to grow at a CAGR of 28.7% Historical
Data 2018–2021 Forecast
Period 2023–2030 Forecast
Units Value
(USD Million/Billion) Report
Coverage Revenue
Forecast, Competitive Landscape, Growth Factors, and Trends Segments
Covered By
Therapy Type, By Application, By End User Geographies
Covered North
America, Europe, Asia Pacific, and Rest of World Growth
Drivers •
Increasing collaboration between the key market players to develop new gene
therapies •
Initiation of research and development activities by the market players for
various disease conditions Restraints
& Challenges •
Unfavorable reimbursement policies •
Challenges associated with cell and gene therapy
Market
Opportunities Cell therapy
segment is expected to hold the largest market share over the forecast period
owing to the growing approvals for various cell therapy products and robust
research and development in this field. Cell therapy aims to replace or
regenerate human cells that are diseased, damaged or lost due to age and
degenerative illness. Various cell therapy products have already been approved
for treatment of cancer, cardiovascular diseases, and musculoskeletal
disorders. For instance, Kymriah by Novartis is a CAR-T cell therapy approved
for treatment of lymphoblastic leukemia and Yescarta by Gilead Sciences is
approved for treatment of lymphoma.
Immediate Delivery Available | Buy This
Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2475
Gene therapy
segment is projected to witness significant growth during the forecast period
due to increasing success rates of gene therapy clinical trials. Gene therapy
involves modification of genes to treat or cure genetic disorders. Some gene
therapies have already been approved to treat inherited retinal diseases,
hemophilia, and neurodegenerative disorders. For instance, Luxturna by Spark
Therapeutics is the first approved gene therapy treatment for an inherited
retinal disease. Several pipeline candidate drugs are also under clinical
trials for various cancers, bleeding disorders, cardiovascular diseases, and
neurological disorders.
Key Market
Takeaways The global cell
and gene therapy market is anticipated to witness a CAGR of 28.7% during the
forecast period. This is owing to growing approval and launch of cell and gene
therapy products. On the basis of
therapy type, cell therapy segment is expected to hold a dominant position,
owing to higher approvals for cell therapy products and robust research
pipelines in this segment. On the basis of
application, dermatology segment is expected to hold a dominant position over
the forecast period due to successful approval of CAR-T and gene therapies for
treatment of skin cancers and disorders. On the basis of
region, North America is expected to hold a dominant position over the forecast
period. This is due to presence of key market players and high adoption of
newly launched cell and gene therapies.
Competitor
Insights - Novartis
International AG - Pfizer Inc., - Sanofi S.A. - Amgen, Inc - Regeneron Pharmaceuticals,
Inc - bluebird Bio,
Inc., - Biogen Inc - uniQure N.V. - JCR
Pharmaceuticals CO. Ltd. - Gene
Biotherapeutics - Kolon
TissueGene Inc., - Horama S.S - MeiraGTx
Limited. - Gilead
Sciences, Inc - Organogenesis,
Inc - Orchard Therapeutics
Plc - Freeline
Therapeutics Ltd - Bristol-Myers
Squibb Company - PTC
Therapeutics, Inc., - Spark
Therapeutics, Inc. - Biomarin
Pharmaceutical Inc
These key
players are focusing on launching new products and expanding their geographical
presence through collaborations and partnerships.
Industrial
Insights in Cell And Gene Therapy Market
Companies like
Orca Bio are conducting trials to improve relapse-free survival rates while
minimizing chronic GvHD complications. For solid tumor treatments, companies
like Triumvira are working with new targeting mechanisms such as Triumvira’s T
cell Antigen Coupler (TAC). This combines autologous and allogeneic approaches
to better identify and combat tumor cells. Progress in treating challenging
cancers like pancreatic cancer and pediatric brain tumors with CAR-T therapies
highlights potential advancements in overcoming resistance in solid tumors.
Ask For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2475
Detailed Segmentation: By Therapy Type: By Application: By End user: By Region:
Find Most Trending Related Reports:
The global recombinant
DNA technology market is estimated to be valued at USD 172.94 Bn in 2024
and is expected to reach USD 327.63 Bn by 2031, exhibiting a compound annual
growth rate (CAGR) of 9.6% from 2024 to 2031.
The global biopharmaceuticals
market was valued at US$ 371.26 Bn in 2022 and is forecast to reach a value
of US$ 654.76 Bn by 2030 at a CAGR of 7.4% between 2023 and 2030.
The global stem
cell therapy market is estimated to be valued at USD 15.15 Bn in 2024 and
is expected to reach USD 63.23 Bn by 2031, exhibiting a compound annual growth
rate (CAGR) of 22.6% from 2024 to 2031.
The global adoptive
cell therapy market is estimated to be valued at US$ 4,932.5 million in
2022 and is expected to exhibit a CAGR of 21.5% during the forecast period
(2022-2030).
The global Stem
Cell Manufacturing market is estimated to be valued at USD 12.8 Bn in 2024
and is expected to reach USD 30.2 Bn by 2031, exhibiting a compound annual
growth rate (CAGR) of 13% from 2024 to 2031.
The global cell
therapy market is estimated to be valued at USD 2,583.8 Mn in 2024 and is
expected to reach USD 4,847.5 Mn by 2031, exhibiting a compound annual growth
rate (CAGR) of 9.4% from 2024 to 2031.
The global immune
cell engineering market size is expected to reach US$ 11.66 Bn by 2030,
from US$ 2.82 Bn in 2023, at a CAGR of 22.5% during the forecast period.
The global CAR
T cell therapy market is estimated to be valued at US$ 2.26 Billion in 2022
and is expected to exhibit a CAGR of 20.9 % during the forecast period
(2022-2030).
About Us:
Coherent Market
Insights is a global market intelligence and consulting organization that
provides syndicated research reports, customized research reports, and
consulting services. We are known for our actionable insights and authentic
reports in various domains including aerospace and defense, agriculture, food
and beverages, automotive, chemicals and materials, and virtually all domains
and an exhaustive list of sub-domains under the sun. We create value for
clients through our highly reliable and accurate reports. We are also committed
in playing a leading role in offering insights in various sectors post-COVID-19
and continue to deliver measurable, sustainable results for our clients.
Contact Us: Mr. Shah Phone: US: +1-650-918-5898 UK: +44-020-8133-4027 AUS: +61-2-4786-0457 India: +91-848-285-0837 Email: sales@coherentmarketinsights.com
Senior Client Partner – Business Development
Coherent Market Insights
